Index - Tech-Science - Good news for those interested in the Janssen vaccine

Yesterday, Canada has one of the most advanced healthcare systems in the world comprehensive approved Janssen’s coronavirus vaccine. This means that vaccination is no longer only allowed for emergency use.

The licensing authority issued the final, comprehensive approval based on the ENSEMBLE study we have already described. This study involved 43,000 people, in which the vaccine provided 85 percent protection against a severe, hospitalization-related course of a disease caused by the coronavirus. The study was conducted in eight different countries on three continents, which is important to ensure that vaccination is effective worldwide, for different epidemiological situations and different health systems in different countries, and for citizens with very different health conditions. It is also noteworthy that the study included a significant proportion of elderly patients, about 35 percent, and 40 percent of participants had some form of chronic illness.

The vaccine was therefore effective in their circles. With this, Janssen’s vaccination was the third in Canada to receive full approval after Pfizer and Moderna.

The news also affects us, as more and more people in Hungary are interested in the Janssen vaccine. More than three million doses have already arrived in Hungary, but the travel regulations give special significance to this, as according to the present situation, patients vaccinated with Sputnik are not legally protected in terms of the countries of destination that are desirable for many of our compatriots.

Although the Russian vaccine is recognized and used in 40 countries around the world, the European Union and the United States, for example, are important exceptions for us. This is why many of our compatriots are interested in the Janssen vaccine as a third vaccine, as a single dose of it is fully protected. The official Hungarian protocol does not currently recommend the combination of Sputnik with Janssen, as both are so-called vector vaccines. It should be added, however, that the issue was also addressed by the manufacturer after the administration of the booster vaccine, i.e. multiple doses of vector vaccine.

In the study, participants received two doses of the Janssen vaccine, and the analyzes showed good results that exceeded almost all expectations.

Janssen is actually an interesting alternative for the one million Hungarians vaccinated with Sinopharm as a third vaccine. Although the Sinopharm vaccine has been approved by the WHO and the US government has announced in an official statement that it wishes to accept it, its position in Europe is still unclear. Although the countries of the European Union are also members of the WHO, in many cases it is not clear whether they accept the protective effect of a vaccine that is not officially recognized in the European Union.

The Janssen vaccine has been reported in the past to cause a very serious illness with blood clots and low platelet counts. The disease occurred almost exclusively in women under the age of 50, which is why the U.S. CDC has one warning issued. Nevertheless, experts in the U.S. and the European Union say the benefits of the vaccine far outweigh its risks, the risk of blood clots is extremely low and the risk of developing them is lower than in those who have not been vaccinated, as the coronavirus infection itself often involves blood clots.

The author is an allergist and clinical immunologist, c. professor.

(Cover image: Janssen is vaccinated with a single-dose coronavirus vaccine at the vaccination station of Petz Aladár County Training Hospital in Győr on June 5, 2021. Photo: Csaba Krizsán / MTI)

Leave a Reply